Ann M. Buchanan

Infectious Disease

2100 Erwin Rd
Durham, NC 27705

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance.

Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance.

Journal: The Pediatric infectious disease journal

Published: February 04, 2026

Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance.

Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance.

Journal: The Pediatric infectious disease journal

Published: February 04, 2026

Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results.

Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results.

Journal: The Pediatric infectious disease journal

Published: May 29, 2025

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.

Journal: EBioMedicine

Published: April 02, 2025

Efficacy and Safety of the Two-Drug Regimen Dolutegravir-Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b Trial.

Efficacy and Safety of the Two-Drug Regimen Dolutegravir-Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b Trial.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: July 26, 2024

A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1.

A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1.

Journal: Journal of clinical pharmacology

Published: June 27, 2024

Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics.

Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics.

Journal: AIDS (London, England)

Published: May 20, 2024

Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective.

Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective.

Journal: International journal of antimicrobial agents

Published: December 01, 2023

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.

Journal: Clinical pharmacokinetics

Published: July 17, 2023

Effect of Food on the Pediatric Dispersible Tablet Formulations of TRIUMEQ and DOVATO in Healthy Adult Participants.

Effect of Food on the Pediatric Dispersible Tablet Formulations of TRIUMEQ and DOVATO in Healthy Adult Participants.

Journal: Pharmaceutics

Published: March 24, 2023

Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.

Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study.

Journal: The lancet. HIV

Published: January 10, 2023

Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.

Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.

Journal: The Pediatric infectious disease journal

Published: November 24, 2021

Showing 1-12 of 31

Last Updated: 09/26/2026